1. Darvishi M, Tosan F, Nakhaei P, Manjili DA, Kharkouei SA, Alizadeh A, et al. Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathol Res Pract. 2023;241:154241.
2. Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023;14:1246682.
3. Kovács N, Szigeti K, Hegedűs N, Horváth I, Veres DS, Bachmann M, et al. Multimodal PET/MRI imaging results enable monitoring the side effects of radiation therapy. Contrast Media Mol Imaging. 2018;2018(1):5906471.
4. Davodabadi F, Sajjadi SF, Sarhadi M, Mirghasemi S, Hezaveh MN, Khosravi S, et al. Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol. 2023;958:176013.
5. Zhao X, Ning Q, Mo Z, Tang S. A promising cancer diagnosis and treatment strategy: Targeted cancer therapy and imaging based on antibody fragment. Artif Cells Nanomed Biotechnol. 2019;47(1):3621-3630.
6. Behl A, Wani ZA, Das NN, Parmar VS, Len C, Malhotra S, et al. Monoclonal antibodies in breast cancer: A critical appraisal. Crit Rev Oncol Hematol. 2023;183:103915.
7. Srivastava A, O’Connor IB, Pandit A, Wall JG. Polymer-antibody fragment conjugates for biomedical applications. React Funct Polym. 2014;39(2):308-329.
8. Alhazmi HA, Albratty M. Analytical techniques for the characterization and quantification of monoclonal antibodies. Pharmaceuticals. 2023;16(2):291.
9. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82(1):775-797.
10. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205-214.
11. Farjami A, Siahi-Shadbad M, Akbarzadehlaleh P, Roshanzamir K, Molavi O. Evaluation of the physicochemical and biological stability of cetuximab under various stress condition. Journal of Pharmacy & Pharmaceutical Sciences. 2019;22:171-190.
12. Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou S-HI, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388(1):44-54.
13. Hu S. Novel sensitizing agents for therapeutic anti-EGFR antibodies: Academic Press; 2022.
14. Liu W, Kang M, Qin Y, Wei Z, Wang R. Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells. Int J Clin Exp Med. 2015;8(2):2182.
15. Bourhis J, Stein A, de Boer JP, Van Den Eynde M, Gold KA, Stintzing S, et al. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treat Rev. 2021;97:102172.
16. Robison J. Monoclonal Antibodies: Applications in Clinical Oncology. Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development. 2016:217-267.
17. Hanck-Silva G, Fatori Trevizan LN, Petrilli R, De Lima FT, Eloy JO, Chorilli M. A critical review of properties and analytical/bioanalytical methods for characterization of Cetuximab. Crit Rev Anal Chem. 2020;50(2):125-135.
18. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11(9):777-792.
19. Matsuda T, Fujimoto A, Igarashi Y. Colorectal cancer: epidemiology, risk factors, and public health strategies. Digestion. 2025;106(2):91-99.
20. García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol. 2019;9:849.
21. Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Diaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol. 2014;20(15):4208.
22. Tamimi A, Tamimi A, Sorkheh F, Asl SM, Ghafari A, Karimi AG, et al. Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. Cancer Rep. 2023;6(5):e1802.
23. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. Journal of Clinical Oncology. 2011;29(25):3419-3426.
24. Qian Y, Qiu M, Wu Q, Tian Y, Zhang Y, Gu N, et al. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Sci Rep. 2014;4(1):7490.
25. Choi MG, Son GW, Choi MY, Jung JS, Rho JK, Ji W, et al. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study. Journal for Immunotherapy of Cancer. 2024;12(3):e008585.
26. Mittelheisser V, Coliat P, Moeglin E, Goepp L, Goetz JG, Charbonnière LJ, et al. Optimal physicochemical properties of antibody–nanoparticle conjugates for improved tumor targeting. Adv Mater. 2022;34(24):2110305.
27. Maddahfar M, Wen S, Hosseinpour Mashkani SM, Zhang L, Shimoni O, Stenzel M, et al. Stable and highly efficient antibody–nanoparticles conjugation. Bioconjug Chem. 2021;32(6):1146-1155.
28. Sanità G, Carrese B, Lamberti A. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front Mol Biosci. 2020;7:587012.
29. Busch RT, Karim F, Weis J, Sun Y, Zhao C, Vasquez ES. Optimization and structural stability of gold nanoparticle–antibody bioconjugates. ACS omega. 2019;4(12):15269-15279.
30. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nano-enabled medical applications. 2020:61-91.
31. Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment. Int J Mol Sci. 2020;21(17):6018.
32. Yu W, Shevtsov M, Chen X, Gao H. Advances in aggregatable nanoparticles for tumor-targeted drug delivery. Chinese chemical letters. 2020;31(6):1366-1374.
33. Malaspina DC, Longo G, Szleifer I. Behavior of ligand binding assays with crowded surfaces: Molecular model of antigen capture by antibody-conjugated nanoparticles. PLoS One. 2017;12(9):e0185518.
34. Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 2016;27(10):2225-2238.
35. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. Journal of controlled release. 2015;200:138-157.
36. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797-802.
37. Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chin Chem Lett. 2017;8(1):63-77.
38. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011;6(4):715-728.
39. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.
40. Jin S-E, Jin H-E, Hong S-S. Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int. 2014;2014(1):814208.
41. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62(2):90-9.
42. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
43. Fang RH, Kroll AV, Zhang L. Nanoparticle‐based manipulation of antigen‐presenting cells for cancer immunotherapy. Small. 2015;11(41):5483-5496.
44. Jalalvand M, Esmaeili F, Falahzadeh K, Mazloumi M, Shahsavari G, Bayat E, et al. Cetuximab scFv-Modified 5-FU Loaded Chitosan Nanoparticles:" A Novel Therapeutic Platform.". Curr Pharm Biotechnol. 2024.
45. Falahzadeh K, Esmaeili F, Nematollahi L, Bayat E, Khoobi M, Mazloomi M, et al. Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment. Cell J. 2024;26(9):530-542.
46. Castro A, Berois N, Malanga A, Ortega C, Oppezzo P, Pristch O, et al. Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors. Int J Biol Macromol. 2021;182:806-814.
47. Sabra R, Billa N, Roberts CJ. An augmented delivery of the anticancer agent, curcumin, to the colon. Reactive and Functional Polymers. 2018;123:54-60.
48. Gréa T, Jacquot G, Durand A, Mathieu C, Gasser A, Zhu C, et al. Subcutaneous Administration of a Zwitterionic Chitosan‐Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies. Adv Mater. 2024;36(13):2308738.
49. Esmaeili F, Aghajani M, Rashti A, Abdollahi M, Faridi-Majidi R, Ghanbari H, et al. Parameters influencing size of electrosprayed chitosan/HPMC/TPP nanoparticles containing alendronate by an artificial neural networks model. Journal of Electrostatics. 2021;112:103598.
50. Sabra R, Billa N, Roberts CJ. Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. Int J Pharm. 2019;572:118775.
51. Maya S, Kumar LG, Sarmento B, Rejinold NS, Menon D, Nair SV, et al. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym. 2013;93(2):661-669.
52. Li D, Chen X, Wang H, Liu J, Zheng M, Fu Y, et al. Cetuximab‐conjugated nanodiamonds drug delivery system for enhanced targeting therapy and 3D Raman imaging. Journal of Biophotonics. 2017;10(12):1636-1646.
53. Zhao D, Zhao X, Zu Y, Li J, Zhang Y, Jiang R, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010:669-677.
54. Solanki R, Rostamabadi H, Patel S, Jafari SM. Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: A critical review. Int J Biol Macromol. 2021;193:528-540.
55. Pan H, Li S, Li M, Tao Q, Jia J, Li W, et al. Anti-CD19 mAb-conjugated human serum albumin nanoparticles effectively deliver doxorubicin to B-lymphoblastic leukemia cells. Pharmazie. 2020;75(7):318-323.
56. Ye Z, Zhang Y, Liu Y, Liu Y, Tu J, Shen Y. EGFR targeted cetuximab-valine-citrulline (vc)-doxorubicin immunoconjugates-loaded bovine serum albumin (BSA) nanoparticles for colorectal tumor therapy. Int J Nanomedicine. 2021:2443-2459.
57. Taleghani AS, Nakhjiri AT, Khakzad MJ, Rezayat SM, Ebrahimnejad P, Heydarinasab A, et al. Mesoporous silica nanoparticles as a versatile nanocarrier for cancer treatment: A review. Journal of Molecular Liquids. 2021;328:115417.
58. Tsai C-P, Chen C-Y, Hung Y, Chang F-H, Mou C-Y. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. Journal of Materials Chemistry. 2009;19(32):5737-5743.
59. Priya V, Mehata AK, Jain D, Singh SK, Muthu MS. Efficient delivery of Abciximab using mesoporous silica nanoparticles: in-vitro assessment for targeted and improved antithrombotic activity. Colloids Surf B Biointerfaces. 2022;218:112697.
60. Wang Y, Huang H-Y, Yang L, Zhang Z, Ji H. Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Sci Rep. 2016;6(1):25468.
61. Chen R, Huang Y, Wang L, Zhou J, Tan Y, Peng C, et al. Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. Biomater Sci. 2021;9(6):2279-2294.
62. Reda M, Ngamcherdtrakul W, Gu S, Bejan DS, Siriwon N, Gray JW, et al. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Lett. 2019;467:9-18.
63. Stanković V, Đurđić S, Ognjanović M, Antić B, Kalcher K, Mutić J, et al. Anti-human albumin monoclonal antibody immobilized on EDC-NHS functionalized carboxylic graphene/AuNPs composite as promising electrochemical HSA immunosensor. Journal of Electroanalytical Chemistry. 2020;860:113928.
64. Banu H, Sethi DK, Edgar A, Sheriff A, Rayees N, Renuka N, et al. Doxorubicin loaded polymeric gold nanoparticles targeted to human folate receptor upon laser photothermal therapy potentiates chemotherapy in breast cancer cell lines. J Photochem Photobiol B. 2015;149:116-128.
65. El Hallal R, Lyu N, Wang Y. Effect of cetuximab-conjugated gold nanoparticles on the cytotoxicity and phenotypic evolution of colorectal cancer cells. Molecules. 2021;26(3):567.
66. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008;68(6):1970-1978.
67. Dash BS, Lu Y-J, Luo S-H, Chen J-P. Cetuximab-conjugated magnetic poly (Lactic-co-glycolic acid) nanoparticles for dual-targeted delivery of irinotecan in glioma treatment. Materials. 2023;16(16):5526.
68. Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget. 2015;6(11):8788.
69. Cho Y-S, Yoon T-J, Jang E-S, Hong KS, Lee SY, Kim OR, et al. Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett. 2010;299(1):63-71.
70. Abuwatfa WH, Awad NS, Pitt WG, Husseini GA. Thermosensitive polymers and thermo-responsive liposomal drug delivery systems. Polymers. 2022;14(5):925.
71. Adabbo G, Andreozzi A, Iasiello M, Vanoli G. Numerical evaluation of heat-triggered drug release via thermo-sensitive liposomes: a comparison between image-based vascularized tumor and volume-averaged porous media models. Int J Heat Mass Transf. 2024;220:124942.
72. Bi H, Xue J, Jiang H, Gao S, Yang D, Fang Y, et al. Current developments in drug delivery with thermosensitive liposomes. Asian J Pharm Sci. 2019;14(4):365-379.
73. Toro-Cordova A, Flores-Cruz M, Santoyo-Salazar J, Carrillo-Nava E, Jurado R, Figueroa-Rodriguez PA, et al. Liposomes loaded with cisplatin and magnetic nanoparticles: physicochemical characterization, pharmacokinetics, and in-vitro efficacy. Molecules. 2018;23(9):2272.
74. Dorjsuren B, Chaurasiya B, Ye Z, Liu Y, Li W, Wang C, et al. Cetuximab-coated thermo-sensitive liposomes loaded with magnetic nanoparticles and doxorubicin for targeted EGFR-expressing breast cancer combined therapy. Int J Nanomedicine. 2020:8201-8215.
75. McDaid WJ, Greene MK, Johnston MC, Pollheimer E, Smyth P, McLaughlin K, et al. Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. Nanoscale. 2019;11(42):20261-20273.
76. Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev. 2010;110(5):2620-2640.
77. Kanegane H, Hoshino A, Okano T, Yasumi T, Wada T, Takada H, et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol Int. 2018;67(1):43-54.
78. Yudhistira T, Da Silva EC, Combes A, Lehmann M, Reisch A, Klymchenko AS. Biotinylated fluorescent polymeric nanoparticles for enhanced immunostaining. Small Methods. 2023;7(4):2201452.
79. Ding C, Huang Y, Shen Z, Chen X. Synthesis and bioapplications of Ag2S quantum dots with near‐infrared fluorescence. Adv Mater. 2021;33(32):2007768.
80. Hashemkhani M, Demirci G, Bayir A, Muti A, Sennaroglu A, Hadi LM, et al. Cetuximab-Ag 2 S quantum dots for fluorescence imaging and highly effective combination of ALA-based photodynamic/chemo-therapy of colorectal cancer cells. Nanoscale. 2021;13(35):14879-14899.
81. Tokarczyk K, Jachimska B. Characterization of G4 PAMAM dendrimer complexes with 5-fluorouracil and their interactions with bovine serum albumin. Colloids Surf A Physicochem Eng Asp. 2019;561:357-363.
82. Hosseini SM, Mohammadnejad J, Yousefnia H, Alirezapour B, Rezayan AH. Development of 177Lu-cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate. Journal of Cancer Research and Clinical Oncology. 2023;149(10):7779-7791.
83. Anajafi T, Mallik S. Polymersome-based drug-delivery strategies for cancer therapeutics. Ther Deliv. 2015;6(4):521-534.
84. Yue S, Zhang Y, Wei Y, Haag R, Sun H, Zhong Z. Cetuximab–polymersome–mertansine nanodrug for potent and targeted therapy of EGFR-positive cancers. Biomacromolecules. 2021;23(1):100-111.
85. Afsharzadeh M, Hashemi M, Mokhtarzadeh A, Abnous K, Ramezani M. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomed Biotechnol. 2018;46(6):1095-1110.
86. Poojari R, Mohanty B, Kadwad V, Suryawanshi D, Chaudhari P, Khade B, et al. Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake. Nanomedicine. 2022;41:102529.
87. Kumari L, Ehsan I, Mondal A, Al Hoque A, Mukherjee B, Choudhury P, et al. Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. Journal of Drug Targeting. 2023;31(5):521-536.
88. Safaei M, Khosravian P, Sheykhshabani SK, Mardani G, Elahian F, Mirzaei SA. Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells. Toxicol Appl Pharmacol. 2022;441:115989.
89. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331-345.
90. Maroni P, Matteucci E, Bendinelli P, Desiderio MA. Functions and epigenetic regulation of Wwox in bone metastasis from breast carcinoma: comparison with primary tumors. Int J Mol Sci. 2017;18(1):75.
91. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009;158(1):1-9.
92. Day KE, Sweeny L, Kulbersh B, Zinn KR, Rosenthal EL. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol. 2013;15(6):722-729.
93. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301-311.
94. Chakravarty R, Goel S, Valdovinos HF, Hernandez R, Hong H, Nickles RJ, et al. Matching the decay half-life with the biological half-life: ImmunoPET imaging with 44Sc-labeled cetuximab Fab fragment. Bioconjug Chem. 2014;25(12):2197-2204.
95. Jalalvand M, Falahzadeh K, Jalalvand A, Mazloumi M, Shahsavari G. Optimization of the expression of recombinant cetuximab single-chain fragment variable and comparative its purification with magnetic nanoparticles and conventional fast protein liquid chromatography. Biointerface Res Appl Chem. 2023.
96. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001;13(6):506-513.
97. Patel AN, Mehnert JM, Kim S. Treatment of recurrent metastatic head and neck cancer: focus on cetuximab. Clin Med Insights Ear Nose Throat. 2012;5:CMENT. S5129.
98. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry. 1994;269(44):27595-27602.
99. Prewett M, Rockwell P, Rockwell R, Giorgio NA, Mendelsohn J, Scher HI, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. Journal of immunotherapy with emphasis on tumor immunology: official journal of the Society for Biological Therapy. 1996;19(6):419-427.
100. Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(8):1935-1940.
101. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. Journal of Biological Chemistry. 1998;273(3):1568-1573.
102. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 1993;37(5):343-349.
103. Tseng S-H, Chou M-Y, Chu I-M. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy. Int J Nanomedicine. 2015:3663-3685.
104. Zhu CN, Chen G, Tian ZQ, Wang W, Zhong WQ, Li Z, et al. Near‐infrared fluorescent Ag2Se–cetuximab nanoprobes for targeted imaging and therapy of cancer. Small. 2017;13(3):1602309.
105. Van Dongen G, Visser G, Vrouenraets M. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev. 2004;56(1):31-52.
106. Schmidt S, Wagner U, Oehr P, Krebs D. Clinical use of photodynamic therapy in gynecologic tumor patients--antibody-targeted photodynamic laser therapy as a new oncologic treatment procedure. Zentralbl Gynakol. 1992;114(6):307-311.
107. Liang BJ, Pigula M, Baglo Y, Najafali D, Hasan T, Huang H-C. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting. Journal of nanobiotechnology. 2020;18(1):1.
108. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685-1691.
109. Van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011;17(10):1315-1319.
110. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16.
111. Savellano MD, Hasan T. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem Photobiol. 2003;77(4):431-439.
112. Abu-Yousif AO, Moor AC, Zheng X, Savellano MD, Yu W, Selbo PK, et al. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. 2012;321(2):120-127.
113. Inglut CT, Baglo Y, Liang BJ, Cheema Y, Stabile J, Woodworth GF, et al. Systematic evaluation of light-activatable biohybrids for anti-glioma photodynamic therapy. Journal of clinical medicine. 2019;8(9):1269.
114. Huang HC, Pigula M, Fang Y, Hasan T. Immobilization of photo‐immunoconjugates on nanoparticles leads to enhanced light‐activated biological effects. Small. 2018;14(31):1800236.
115. Spring BQ, Abu-Yousif AO, Palanisami A, Rizvi I, Zheng X, Mai Z, et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A. 2014;111(10):E933-E942.
116. Li B, Jiang Z, Xie D, Wang Y, Lao X. Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment. Int J Nanomedicine. 2018:7289-7302.
117. Ashton JR, Gottlin EB, Patz Jr EF, West JL, Badea CT. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. PLoS One. 2018;13(11):e0206950.
118. Ma Y, Peng X, Wang L, Li H, Cheng W, Zheng X, et al. Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment. Sci Technol Adv Mater. 2020;21(1):856-866.
119. Freeman AC, Platt SR, Holmes S, Kent M, Robinson K, Howerth E, et al. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas. Journal of Neuro-Oncology. 2018;137(3):653-663.
120. Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, et al. Half-Chain cetuximab nanoconjugates allow multitarget therapy of triple negative breast cancer. Bioconjug Chem. 2018;29(11):3817-3832.
121. Yang X, Wang Y, Chen S, Zhang S, Cui C. Cetuximab-modified human serum albumin nanoparticles co-loaded with doxorubicin and MDR1 siRNA for the treatment of drug-resistant breast tumors. Int J Nanomedicine. 2021:7051-7069.
122. Salim EI, Mosbah AM, Elhussiny F, Hanafy NA, Abdou Y. Preparation and characterization of cetuximab-loaded egg serum albumin nanoparticles and their uses as a drug delivery system against Caco-2 colon cancer cells. Cancer Nanotechnol. 2023;14(1):4.
123. Wang J-k, Zhou Y-y, Guo S-j, Wang Y-y, Nie C-j, Wang H-l, et al. Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy. Mater Sci Eng C. 2017;76:944-950.
124. Yang C, Tan Y, Qi H, Zhou J, Long L, Zhan Q, et al. Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab. Cancer Biol Med. 2020;17(2):433-443.
125. Lee Y-S, Chin Y-T, Yang Y-CS, Wei P-L, Wu H-C, Shih A, et al. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. Steroids. 2016;111:63-70.
126. Yang J, Lim E-K, Lee HJ, Park J, Lee SC, Lee K, et al. Fluorescent magnetic nanohybrids as multimodal imaging agents for human epithelial cancer detection. Biomaterials. 2008;29(16):2548-2555.
127. Zhang H, Hou X, Lin M, Wang L, Li H, Yuan C, et al. The study on the preparation and characterization of gene-loaded immunomagnetic albumin nanospheres and their anti-cell proliferative effect combined with magnetic fluid hyperthermia on GLC-82 cells. Drug Des Devel Ther. 2015:6445-6460.
128. Ferreira NN, Granja S, Boni FI, Ferreira LM, Reis RM, Baltazar F, et al. A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems. Drug Deliv Transl Res. 2020;10(3):594-609.
129. Jha A, Viswanadh MK, Burande AS, Mehata AK, Poddar S, Yadav K, et al. DNA biodots based targeted theranostic nanomedicine for the imaging and treatment of non-small cell lung cancer. Int J Biol Macromol. 2020;150:413-425.
130. Abdellatif AA, Tolba NS, Alsharidah M, Al Rugaie O, Bouazzaoui A, Saleem I, et al. PEG-4000 formed polymeric nanoparticles loaded with cetuximab downregulate p21 & stathmin-1 gene expression in cancer cell lines. Life Sci. 2022;295:120403.
